ZA200806094B - Methods for obtaining immortalized antibody secreting cells - Google Patents

Methods for obtaining immortalized antibody secreting cells

Info

Publication number
ZA200806094B
ZA200806094B ZA200806094A ZA200806094A ZA200806094B ZA 200806094 B ZA200806094 B ZA 200806094B ZA 200806094 A ZA200806094 A ZA 200806094A ZA 200806094 A ZA200806094 A ZA 200806094A ZA 200806094 B ZA200806094 B ZA 200806094B
Authority
ZA
South Africa
Prior art keywords
methods
cells
human
secrete
secreting cells
Prior art date
Application number
ZA200806094A
Other languages
English (en)
Inventor
Garotta Gianni
Funaro Ada
Murphy Marianne
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Publication of ZA200806094B publication Critical patent/ZA200806094B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200806094A 2005-12-16 2008-07-14 Methods for obtaining immortalized antibody secreting cells ZA200806094B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2005056871 2005-12-16

Publications (1)

Publication Number Publication Date
ZA200806094B true ZA200806094B (en) 2009-06-24

Family

ID=36685876

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200806094A ZA200806094B (en) 2005-12-16 2008-07-14 Methods for obtaining immortalized antibody secreting cells
ZA200904907A ZA200904907B (en) 2005-12-16 2009-07-14 Antibodies against human cytomegalovirus (hCMV)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200904907A ZA200904907B (en) 2005-12-16 2009-07-14 Antibodies against human cytomegalovirus (hCMV)

Country Status (19)

Country Link
US (1) US8338172B2 (fr)
EP (1) EP1974020B1 (fr)
JP (2) JP5431730B2 (fr)
KR (1) KR101508945B1 (fr)
CN (1) CN101374944B (fr)
AT (1) ATE513034T1 (fr)
AU (1) AU2006325236B2 (fr)
BR (1) BRPI0619908A2 (fr)
CA (1) CA2633601C (fr)
DK (1) DK1974020T3 (fr)
EA (1) EA019505B1 (fr)
ES (1) ES2367322T3 (fr)
IL (1) IL192095A0 (fr)
NO (1) NO20083160L (fr)
NZ (1) NZ569816A (fr)
PL (1) PL1974020T3 (fr)
PT (1) PT1974020E (fr)
WO (1) WO2007068758A1 (fr)
ZA (2) ZA200806094B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US8202518B2 (en) 2007-07-04 2012-06-19 Ribovax Biotechnologies S.A. Antibodies against human cytomegalovirus (HCMV)
WO2009020923A1 (fr) 2007-08-03 2009-02-12 Musc Foundation For Research Development Anticorps monoclonaux humains et procédés de production
WO2009024445A1 (fr) * 2007-08-22 2009-02-26 Ribovax Biotechnologies Sa Anticorps dirigés contre le cytomégalovirus humain (hcmv)
PE20141435A1 (es) 2008-07-16 2014-10-22 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
EP2342350A4 (fr) 2008-09-23 2012-05-30 Hema Quebec Procédé pour la fabrication d'immunoglobulines g polyclonales par des lymphocytes b humains
PL2464664T3 (pl) 2009-08-13 2016-02-29 Crucell Holland Bv Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
WO2011076883A1 (fr) 2009-12-23 2011-06-30 4-Antibody Ag Eléments de liaison pour cytomégalovirus humain
PL2400298T3 (pl) * 2010-05-28 2014-01-31 Hoffmann La Roche Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał
PH12012502244A1 (en) 2010-07-09 2016-09-30 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN102839152A (zh) * 2011-06-20 2012-12-26 中国科学院上海生命科学研究院 一种快速高效获得抗原特异性b细胞的方法
WO2013000982A1 (fr) 2011-06-27 2013-01-03 Vivalis Procédé de criblage de cellules
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
ES2668104T3 (es) 2011-12-28 2018-05-16 Immunoqure Ag Procedimiento de aislamiento de anticuerpos humanos
US20140199319A1 (en) * 2012-12-14 2014-07-17 Abbvie, Inc. Methods for increasing the efficiency of hybridoma generation
EP2941441A1 (fr) * 2013-01-03 2015-11-11 Merck Patent GmbH Procédé de production d'anticorps sécrétables par expression dans saccharomyces cerevisiae
WO2015001047A1 (fr) 2013-07-03 2015-01-08 Immunoqure Ag Procédé donnant des anticorps anti-cytokine humaine à usage pharmaceutique
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6916884B2 (ja) * 2017-01-02 2021-08-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ細胞培養法
US11572389B2 (en) 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111647566A (zh) * 2019-07-10 2020-09-11 广州医科大学附属第一医院 一种高滴度eb病毒的制备方法、eb病毒永生化记忆性b细胞的方法与应用
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN117230258B (zh) * 2023-11-10 2024-04-09 苏州驾玉生物医药有限公司 一种提高灵敏度的培养扩增联合pcr的eb病毒检测方法
CN119285758B (zh) * 2024-10-31 2025-07-01 上海百英生物科技股份有限公司 一种基于b细胞永生化的单个b细胞抗体开发方法及其应用
CN120272432B (zh) * 2025-03-25 2025-12-26 佛山市妇幼保健院 一种脊髓性肌萎缩症质控品及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
EP0493433B1 (fr) * 1989-09-19 1996-01-10 Centocor, Inc. Procede d'amelioration de la production d'anticorps monoclonaux humains et cellules utilisees dans ce procede
DE59109273D1 (de) 1990-02-01 2010-01-07 Siemens Healthcare Diagnostics Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6399384B1 (en) * 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
FR2817875B1 (fr) 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
GB2398783A (en) * 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
WO2004076677A2 (fr) * 2003-02-26 2004-09-10 Institute For Research In Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
WO2007049152A2 (fr) * 2005-08-23 2007-05-03 Iq Corporation Procedes pour produire des lymphocytes b stables

Also Published As

Publication number Publication date
CN101374944B (zh) 2012-02-08
NO20083160L (no) 2008-09-10
PL1974020T3 (pl) 2011-11-30
EA200870062A1 (ru) 2009-04-28
EP1974020B1 (fr) 2011-06-15
PT1974020E (pt) 2011-08-26
EA019505B1 (ru) 2014-04-30
HK1127783A1 (en) 2009-10-09
KR101508945B1 (ko) 2015-04-08
ES2367322T3 (es) 2011-11-02
AU2006325236A1 (en) 2007-06-21
ZA200904907B (en) 2010-04-28
US8338172B2 (en) 2012-12-25
BRPI0619908A2 (pt) 2011-10-25
JP5431730B2 (ja) 2014-03-05
AU2006325236B2 (en) 2011-11-10
CA2633601C (fr) 2015-06-30
JP2013255515A (ja) 2013-12-26
KR20080097181A (ko) 2008-11-04
DK1974020T3 (da) 2011-10-03
US20090270268A1 (en) 2009-10-29
ATE513034T1 (de) 2011-07-15
NZ569816A (en) 2011-10-28
CN101374944A (zh) 2009-02-25
IL192095A0 (en) 2008-12-29
WO2007068758A1 (fr) 2007-06-21
JP2009519026A (ja) 2009-05-14
EP1974020A1 (fr) 2008-10-01
CA2633601A1 (fr) 2007-06-21

Similar Documents

Publication Publication Date Title
IL192095A0 (en) Methods for obtaining immortalized antibody secreting cells
US12351825B2 (en) Soluble antibody complexes for T cell or NK cell activation and expansion
PH12020500160A1 (en) Reagents for expanding cells expressing recombinant receptors
Stemberger et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting
TW200714711A (en) Anti-cd-20 monoclonal antibody
MY150553A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
AU2018338418A1 (en) Anti-HLA-A2 antibodies and methods of using the same
EA202190608A1 (ru) Однодоменные анти-bcma антитела и их применение
Dang et al. Soluble CD27 induces IgG production through activation of antigen‐primed B cells
MX2021014966A (es) Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso.
MX2022013956A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion especificas de cd70.
WO2009035738A3 (fr) Utilisation d'une analyse elispot de cellules sécrétrices d'anticorps pour évaluer les réponses des anticorps suite à leur exposition à un antigène
WO2011050985A8 (fr) Expansion clonale de lymphocytes b
Correa et al. Evaluation of antigen-conjugated fluorescent beads to identify antigen-specific B cells
Vásquez et al. Rapid proliferation and differentiation of a subset of circulating IgM memory B cells to a CpG/cytokine stimulus in vitro
Scholzen et al. Expansion of IgG+ B-cells during mitogen stimulation for memory B-cell ELISpot analysis is influenced by size and composition of the B-cell pool
WO2009045075A3 (fr) Anticorps monoclonal spécifique des cellules souches embryonnaires humaines, hybridome sécrétant ce dernier et procédé permettant de détecter ou d'isoler une cellule souche embryonnaire non différenciée
Barbeau et al. Generation of a human induced pluripotent stem cell line (iPSC) from peripheral blood mononuclear cells of a patient with a myasthenic syndrome due to mutation in COLQ
Vazaios et al. Boosting CAR T-cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas
Rybkina The landscape and interplay of antiviral immunity mounted against SARS-CoV-2 infection across tissues, age, and disease
WO2006089002A3 (fr) Methode de criblage a haut rendement d'anticorps et de proteines induisant l'apoptose
UA72439U (ru) Тест-система иммуноферментная для качественного и полуколичественного определения антител класса igg к вирусам простого герпеса 2 типа, унифицированная "dia-hsv 2-igg-u"
UA72423U (ru) ИММУНОФЕРМЕНТНАЯ ТЕСТ-СИСТЕМА ДЛЯ КОЛИЧЕСТВЕННОГО АНАЛИЗА И ОПРЕДЕЛЕНИЯ АВИДНОСТИ АНТИТЕЛ КЛАССА IgG ВИРУСА КРАСНУХИ (DIA-RUBELLA-IGG-AV)
RU2016122025A (ru) Клон культивируемых гибридных клеток животного mus musculus l. rv-4 - продуцент моноклональных антител, специфичных к рибонуклеопротеину вируса бешенства (n-белку)